ZNF252P and ovarian carcinoma: As seen in Fig. 3.C, the expression of N-cadherin, vimentin, MMP2 and MMP9 was significantly reduced when ZNF252P-AS1 was inhibited in ovarian cancer cells, whereas E-cadherin was dramatically up-regulated.